Inicio>>Signaling Pathways>> Microbiology & Virology>> Bacterial>>Loganetin

Loganetin

Catalog No.GC32290

Loganetin es un producto natural no tÓxico que se puede aplicar en el desarrollo de fÁrmacos antibacterianos para el tratamiento de infecciones Gram negativas multirresistentes.

Products are for research use only. Not for human use. We do not sell to patients.

Loganetin Chemical Structure

Cas No.: 29748-10-5

Tamaño Precio Disponibilidad Cantidad
5mg
230,00 $
Disponible
10mg
349,00 $
Disponible

Tel:(909) 407-4943 Email: sales@glpbio.com


Reseñas de cliente

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Loganetin is a non-toxic natural product that may be applied in the antibacterial drug development for treating multidrug-resistant Gram negative infections.

Although Loganetin does not possess antibacterial activity of its own, but in combination, it appreciably reduces the minimum inhibitory concentration (MIC) of nalidixic acid (NA) against nalidixic acid resistant (NAREC) and nalidixic acid sensitive (NASEC) strains of Escherichia coli. Loganetin, a very common, inexpensive, and non-toxic natural product may finds its application in the antibacterial drug development for treating multidrug-resistant Gram negative infections[1].

[1]. Anupam Maurya, et al. Preparative Isolation of Bioenhancer Loganetin from sf Alstonia scholaris by Fast Centrifugal Partition Chromatography. Separation Science and Technology Volume 49, 2014-Issue 5.

Reseñas

Review for Loganetin

Average Rating: 5 ★★★★★ (Based on Reviews and 30 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Loganetin

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.